
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc demonstrates a positive outlook due to projected growth in its PSMA PET imaging revenue, with estimates indicating an increase from a low to mid-single digit market share to a high-single digit share by 1Q25. The introduction of a new Pylarify formulary is expected to enhance production capabilities and contribute to growth in Pylarify revenues beginning in 4Q26, bolstered by eligibility for three years of unique production through TPT. Additionally, there is a strong potential for increased earnings per share in 2026-2027 if Lantheus's non-Pylarify segments outperform expectations and provide a substantial contribution to revenue growth and margins.
Bears say
Lantheus Holdings Inc is facing a negative outlook primarily due to a decline in its revenue from Pylarify, which reported $260 million, a decrease of 8% year-over-year and falling short of expectations by approximately $14 million. Additionally, unit growth was lower than anticipated, registering only a 2% increase year-over-year and experiencing a significant price headwind of 10% during the quarter. These factors contribute to a reduced growth profile for Lantheus relative to its profitable SMID MedTech peers, with revised forecasts for 2025-2026 suggesting further challenges ahead.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares